- Home
- OTAI vs ANIX Comparison
OTAI vs ANIX Comparison
Compare OTAI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTAI | ANIX |
|---|---|---|
| Founded | N/A | 1982 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 114.0M |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OTAI | ANIX |
|---|---|---|
| Price | $10.00 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 3.6K | ★ 284.9K |
| Earning Date | N/A | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.32 |
| 52 Week High | $10.73 | $5.46 |
Technical Indicators
Market Signals| Indicator | OTAI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 27.73 |
| Support Level | $9.93 | $2.73 |
| Resistance Level | $10.03 | $3.09 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 8.84 | 6.60 |
Price Performance
Historical ComparisonAbout OTAI Starlink AI Acquisition Corporation Ordinary Shares
Starlink AI Acquisition Corp is a blank check company.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.